CA-BIOCYTOGEN
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today announced that it has entered into an antibody evaluation and option agreement with Neurocrine Biosciences, Inc. The agreement grants Neurocrine Biosciences access to Biocytogen’s fully human antibodies against multiple specified targets, with an option to license selected antibodies for therapeutic product development, manufacturing and commercialization for all uses worldwide. Additional targets may be included under this agreement subject to mutual agreement. The antibodies were generated by Biocytogen’s proprietary RenMice® platforms.
Under the terms of the agreement, if options are exercised, Biocytogen will be entitled to option-exercise fees, development and commercialization milestone payments, as well as single-digit royalties on net sales for each selected target.
Dr. Yuelei Shen, President and CEO of Biocytogen, said, “We are pleased that our RenMice®-derived fully human antibodies received recognition from Neurocrine Biosciences, a world-leading neuroscience-focused biopharmaceutical company. We are optimistic that the combination of our comprehensive, validated off-the-shelf antibody sequences and Neurocrine’s extensive experience in novel drug development will accelerate the path to help conquer neurological diseases that are difficult to treat.”
“We are excited to evaluate the therapeutic potential of antibodies generated from Biocytogen’s renowned fully human antibody platforms,” said Jude Onyia, Ph.D., Chief Scientific Officer at Neurocrine Biosciences. “We believe this collaboration will help expand our pipeline with antibody-based drugs and ultimately provide patients with improved treatment options.”
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® (RenMabTM/RenLite®/RenNano®/RenTCR-mimicTM) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. As of June 30, 2023, 50 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and 42 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company’s sub-brand, BioMiceTM, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco), and Germany (Heidelberg). For more information, please visit http://en.biocytogen.com.cn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231219983706/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Venture Global Announces Long-term Sales and Purchase Agreement With Naturgy of Spain10.11.2025 13:00:00 CET | Press release
Venture Global’s second long-term contract with a Spanish company5.75 MTPA of long-term contracts signed by Venture Global to date in 2025 Today, Venture Global, Inc. (NYSE:VG) and Naturgy announced the execution of a new long-term Sales and Purchase Agreement (SPA) for the purchase of 1 million tonnes per annum (MTPA) of liquefied natural gas (LNG) from Venture Global for twenty years beginning in 2030. The agreement represents Spain’s first long-term contract for American LNG since Venture Global’s first contract in 2018. To date, Venture Global has supplied Spain with 35 cargoes from its Calcasieu Pass and Plaquemines facilities. “Venture Global is honored to expand our long-term partnership with Spain through this new agreement with Naturgy, a leading global LNG company,” said Mike Sabel, CEO of Venture Global. “This contract will positively impact the U.S. balance of trade with Spain and enhance energy security across the region. Our unmatched speed and execution have made Venture
71% of Global Businesses Have Accelerated AI Adoption Amid Tariffs, Inflation and Uncertainty, Finds Economist Study Commissioned by Kinaxis10.11.2025 13:00:00 CET | Press release
Geopolitical turbulence is pushing AI to the forefront of the innovation agenda, but many supply chains are not ready According to Supply Chain’s Big Bet on AI For Geopolitical Resilience, a new global study from Economist Impact, commissioned by Kinaxis® Inc. (TSX:KXS), while 71% of companies have accelerated AI deployment in response to tariffs, inflation, and geopolitical volatility, a wide gap remains between AI ambition and implementation, according to Economist Impact. Nearly every company (97%) is experimenting with AI, but only 20% can make real-time decisions, and just 22% have a defined AI strategy, and those with one are more than three times as likely to see measurable ROI. Moreover, while business leaders tend to underestimate the new risks and complexities that AI may introduce, staff are more focused on the practical realities with the effort, change management, and technical challenges involved in turning AI ambition into everyday impact. “Disruption is no longer cyclic
The LYCRA Company Announces Grand Opening of Its Largest Global Spandex Production Facility in China10.11.2025 13:00:00 CET | Press release
The LYCRA Company, a global leader in innovative and sustainable fiber solutions for the apparel and personal care industries, today announced the official opening of its largest spandex production facility—the LYCRA® fiber (Yinchuan) Plant in Ningxia Province, China. This milestone underscores the company’s continued investment in the Chinese market and highlights its strong commitment to developing localized supply and distribution networks while advancing smart manufacturing upgrades. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251110715151/en/ Executives and local dignitaries gathered to celebrate the grand opening of The LYCRA Company's state-of-the-art spandex manufacturing facility in Yinchuan, China, on November 7, marking a significant milestone in regional investment and the company's strong commitment to developing localized supply and distribution networks. With a total investment of more than RMB 800 million,
Ookla Unveils Speedtest Pulse™, Redefining Network Validation and Troubleshooting10.11.2025 12:00:00 CET | Press release
Disruptive new diagnostic device puts 20 years of network expertise in the hands of ISPs and enterprises, empowering them to validate performance, end costly repeat visits, and boost customer satisfaction. Ookla®, a global leader in connectivity intelligence, today unveiled Speedtest Pulse™, a new network diagnostic device designed to provide definitive, smartphone-based validation and troubleshooting for internet service providers (ISPs) and enterprises. Leveraging the power of Speedtest®, a globally trusted gold standard for connectivity measurement, Speedtest Pulse bridges a crucial gap in technician toolkits, offering a powerful, scalable solution that is easy to use and provides clear, actionable insights. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251110605367/en/ Speedtest Pulse™ is a dual-mode network diagnostic tool offering one-tap, smartphone-based validation and troubleshooting, and autonomous testing of netw
Kaneka Expands Global Reach with i-ED COIL™ Launch in Europe10.11.2025 03:51:00 CET | Press release
Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Kazuhiko Fujii) (TOKYO:4118) has begun sales of its i-ED COIL™, a brain aneurysm embolization coil (*1), in Europe as of October. The product obtained EC certification (*2) under an EU Medical Device Regulation (*3) in July and will be distributed primarily in Europe through Kaneka Medical Europe N.V. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251109744229/en/ i-ED Coil The i-ED COIL™ provides world-class flexibility, enabled by its specialized wire thickness and structural features. This flexibility enables coils to be packed more densely within aneurysms than conventional products and allows treatment of aneurysms with irregular shapes. Its role in reducing the risk of aneurysm rupture is highly regarded by physicians, and since its launch in the Japanese market in 2019, sales have continued to grow steadily. Kaneka is expanding its business in a wide range
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom